Despite these significant findings, current research has predominantly focused on elucidating the role of ELOVL2 in PCa pathogenesis, with a notable paucity of systematic investigations exploring its potential involvement in therapeutic resistance. Here, ELOVL2 is linked to posterior cortical atrophy.